NEW YORK (GenomeWeb News) – Sigma Life Science has reached a deal to license its CompoZr Zinc Finger Nuclease technology to Horizon Discovery on a non-exclusive basis, Sigma-Aldrich announced today.

Under the terms of the deal, Horizon will use the technology for the commercial development of cell-based products and to provide commercial gene editing services. Additional terms were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.